Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity

Cytotherapy

Volumn 14, Issue 2, 2012, Pages 173-181

  Poonia, Bhawna ^a   Pauza, C David ^a  

^a INSTITUTE OF HUMAN VIROLOGY   (United States)

Author keywords

Antibody dependent cellular cytotoxicity; Human immunodeficiency virus; Immunotherapy; Zoledronate; T cells

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD16 ANTIGEN; CD56 ANTIGEN; CYTOKINE; FC RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 2; ISOPENTENYL DIPHOSPHATE; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL EXPANSION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPHENOTYPING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84855864129     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.623693     Document Type: Article

References (24)

1. Wren L, Kent SJ. HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity. Hum Vaccin. 2011, 466-73.
2. + NK cells: a functional intermediate stage of NK cell differentiation. J Immunol. 2011;186:6753-61.
3. Angelini DF, Borsellino G, Poupot M, Diamantini A, Poupot R, Bernardi G, et al. FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood. 2004;104:1801-7. (Pubitemid 39202290)
4. Gertner-Dardenne J, Bonnafous C, Bezombes C, Capietto AH, Scaglione V, Ingoure S, et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood. 2009;113:4875-84.
5. Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, Fai-So H, et al. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs ritux-imab and trastuzumab. Int J Cancer. 2008;122:2526-34. (Pubitemid 351590486)
6. Mattarollo SR, Kenna T, Nieda M, Nicol AJ. Chemotherapy and zoledronate sensitize solid tumour cells to Vy9 V62 T cell cytotoxicity. Cancer Immunol Immunother. 2007;56:1285-97. (Pubitemid 46763941)
7. Poccia F, Gioia C, Martini F, Sacchi A, Piacentini P, Tempestilli M, et al. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells. AIDS. 2009;23: 555-65.
8. Kottilil S, Jackson JO, Reitano KN, O'Shea MA, Roby G, Lloyd M, et al. Innate immunity in HIV infection: enhanced susceptibility to CD95-mediated natural killer cell death and turnover induced by HIV viremia. J Acquir Immune Defic Syndr. 2007;46:151-9. (Pubitemid 47482610)
9. Cummings JS, Cairo C, Armstrong C, Davis CE, Pauza CD. Impacts of HIV infection on Vy2 V82 T cell phenotype and function: a mechanism for reduced tumor immunity in AIDS. J Leukoc Biol. 2008;84:371-9.
10. Hebbeler AM, Propp N, Cairo C, Li H, Cummings JS, Jacobson LP, et al. Failure to restore the Vgamma2-Jgamma1.2 repertoire in HIV-infected men receiving highly active antiretroviral therapy (HAART). Clin Immunol. 2008;128: 349-57.
11. Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C, et al. In vivo effects of zoledronic acid on peripheral y8 T lymphocytes in early breast cancer patients. Cancer Immunol Immunother. 2009;58:31-8.
12. Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab. 2007;92:1283-8. (Pubitemid 46556399)
13. + NK cells in vitro. J Immunol. 2000;165:1659-64. (Pubitemid 30604605)
14. +{gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res. 2008;14:4232-40.
15. + T cells closely correlates with CD56 surface expression. J Immunol. 2000;164:1148-52. (Pubitemid 30067223)
16. Klein JS, Webster A, Gnanapragasam PN, Galimidi RP, Bjork-man PJ. A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity. AIDS. 2010;24:1633-40.
17. Wesch D, Marx S, Kabelitz D. Comparative analysis of alpha beta and gamma delta T cell activation by Mycobacterium tuberculosis and isopentenyl pyrophosphate. Eur J Immunol. 1997;27:952-6. (Pubitemid 27155331)
18. Naoe M, Ogawa Y, Takeshita K, Morita J, Shichijo T, Fuji K, et al. Zoledronate stimulates gamma delta T cells in prostate cancer patients. Oncol Res. 2010;18:493-501.
19. Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol. 2010;161:290-7.
20. Benzaid I, Monkkonen H, Stresing V, Bonnelye E, Green J, Monkkonen J, et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote V {gamma}9V{delta}2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res. 2011;71:4562-72.
21. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009;5:e1000433.
22. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005;366:549-55. (Pubitemid 41140329)
23. Kovochich M, Marsden MD, Zack JA. Activation of latent HIV using drug-loaded nanoparticles. PLoS One. 2011;6:e18270.
24. Noguchi A, Kaneko T, Kamigaki T, Fujimoto K, Ozawa M, Saito M, et al. Zoledronate-activated Vgamma9gammadelta T cell-based immunotherapy is feasible and restores the impairment of gammadelta T cells in patients with solid tumors. Cytotherapy. 2011;13:92-7.